Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

Abstract Objectives The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. Methods We conducted a randomized, double-blinded, parallel, positive control design, multicenter stud...

Full description

Bibliographic Details
Main Authors: Hua Ye, Shengyun Liu, Jian Xu, Kexia Chai, Dongyi He, Yongfei Fang, Qibing Xie, Huaxiang Liu, Ying Liu, Bingzhu Hua, Jiankang Hu, Zhiyi Zhang, Mingxuan Zhou, Dongbao Zhao, Yan Li, Zhenyu Jiang, Meimei Wang, Jingyang Li, Zhuoli Zhang, Xiaomei Li, Yang Li, Erwei Sun, Liqi Bi, Wei Wei, Ning Tie, Lan He, Xiangyang Huang, Yan Zhang, Qingchun Huang, Xiaofei Wang, Xiangyuan Liu, Jing Li, Yin Su
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Rheumatology and Therapy
Subjects:
Infliximab
CMAB008
Biosimilar
Rheumatoid arthritis
Clinical equivalence
Online Access:https://doi.org/10.1007/s40744-023-00544-2

Internet

https://doi.org/10.1007/s40744-023-00544-2

Similar Items